The information was generated by an EvaluatePharma analysis cited by Pharm Exec magazine.
Pfizer ($45.3 billion in Rx sales)
1. Prevnar 13 ($5.8 billion)
2. Lyrica ($4.97 billion)
3. Ibrance ($4.12 billion
Roche ($44.55 billion in Rx sales)
1. Herceptin ($7.14 billion)
2. Avastin ($7 billion)
3. Rituxan (6.91 billion)
Novartis ($43.48 billion in Rx sales)
1. Gilenya ($3.34 billion)
2. Cosentyx ($2.84 billion)
3. Lucentis ($2.05 billion)
Johnson & Johnson ($38.82 billion in Rx sales)
1. Stelara ($5.16 billion)
2. Remicade ($4.89 billion)
3. Zytiga ($3.5 billion)
Merck & Co. ($37.35 billion in Rx sales)
1. Keytruda ($7.17 billion)
2. Januvia (3.69 billion)
3. Gardasil ($3.15 billion)
Sanofi ($35.12 billion in Rx sales)
1. Lantus ($4.21 billion)
2. Pentacel ($2.07 billion)
3. Fluzone ($2.02 billion)
AbbVie ($32.07 billion in Rx sales)
1. Humira ($19.94 billion)
2. Mavyret ($3.44 billion)
3. Imbruvica ($2.97 billon)
GlaxoSmithKline ($30.65 billion in Rx sales)
1. Triumeq ($3.54 billion)
2. Advair ($3.23 billion)
3. Tivicay ($2.19 billion
Amgen ($22.53 billion in Rx sales)
1. Enbrel ($5.01 billion)
2. Neulasta ($4.48 billion)
3. Prolia ($2.29 billion)
Gilead Sciences ($21.68 billion in Rx sales)
1. Genvoya ($4.62 billion)
2. Truvada ($2.3 billion)
3. Epclusa ($1.97 billion)
More articles on pharmacy:
Sanofi poaches exec from Novartis
Eli Lilly’s migraine drug 1st approved to reduce cluster headaches: 4 notes
EpiPen shortage will drag on: 4 things to know
